

Diese Meldung kann unter <http://www.presseportal.de/pm/69246/1097422/new-data-reinforces-the-superiority-of-escitalopram-over-duloxetine-for-acute-treatment-of> abgerufen werden.

H. Lundbeck A/S

New Data Reinforces the Superiority of Escitalopram Over Duloxetine for Acute Treatment of Depression

05.12.2007 - 14:14 Uhr, H. Lundbeck A/S

Copenhagen (ots/PRNewswire) - - Attention Medical Trade Press Only

- Further Study Demonstrates Efficacy and Tolerability of Escitalopram in Premenstrual Dysphoric Disorder

New data released today reinforces the superiority of escitalopram compared to duloxetine in the acute treatment of depression and provides a further insight into the impact of antidepressants on patient functioning and quality of life - an important consideration for physicians and patients.(1,2)

The study, presented at the International Forum on Mood and Anxiety Disorders (IFMAD) in Budapest, Hungary, reports on a pooled analysis of two studies, both comparing the efficacy and tolerability of escitalopram (an allosteric serotonin reuptake inhibitor - ASRI) and duloxetine (a serotonin and noradrenaline reuptake inhibitor - SNRI).(1)

Important findings from the study:

- Patients taking escitalopram demonstrated significantly greater improvement in depression symptoms (as measured by the MADRS scale) at weeks 1,2, 4 and 8 with the mean treatment difference at week 8 being 2.6 points (p

Originaltext:

H. Lundbeck A/S

Pressemappe:

<http://www.presseportal.de/pm/69246/h-lundbeck-a-s>

Pressemappe als RSS:

http://presseportal.de/rss/pm_69246.rss2